ABL-directed inhibitors, commonly named tyrosine kinase inhibitors (TKIs), represented by first-generation Imatinib (IM), second-Nilotinib, Dasatinib (DAS), Bosutinib (BOS) and third-generation Ponatinib (PON), are the first line treatment for CML and Ph+ B-ALL patients, inducing complete hematological, molecular and cytogenetic responses [2,3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.